Clinical Trial Description

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)


This study is a phase III double blind, placebo controlled, study with a randomization allocation ratio of 1:1 (radium-223 dichloride plus abiraterone acetate plus prednisone: placebo plus abiraterone acetate plus prednisone).The study period will consist of screening/randomization, treatment, active follow-up with clinic visits, active follow-up without clinic visits, and long-term follow-up phases. In this study, subjects will receive study treatment (radium-223 dichloride or placebo in addition to abiraterone acetate plus prednisone for the first 6 cycles followed by abiraterone acetate plus prednisone thereafter).Contact: Elisa Blackwell CRC 520-202-3606” target=”_blank”>520-202-3606 for more information. Learn More from NIH >